June 2026 in “Frontiers in Immunology” This review highlights the potential for JAK inhibitors to effectively treat inflammatory and autoimmune skin diseases by targeting the JAK-STAT signaling pathway, advocating for an integrated approach to enhance targeted therapy.
4 citations
,
July 2025 in “Frontiers in Immunology” This study explored peripheral blood immune dysregulation in alopecia areata through single-cell analyses, identifying systemic changes linked to disease severity and key signaling roles for monocytes, NK cells, and memory T cells, suggesting potential therapeutic targets.
18 citations
,
August 2024 in “eLife” This study investigated immune dysregulation in individuals with Down syndrome and found that treatment with the JAK inhibitor tofacitinib improved skin conditions like alopecia areata and reduced autoimmune markers without severe side effects. Additional research is necessary to understand its broader impacts.
2 citations
,
December 2024 in “eLife” This study observed that individuals with Down syndrome exhibit early immune dysregulation, including multi-organ autoimmunity and hypercytokinemia, and found that the JAK inhibitor tofacitinib showed a good safety profile and reduced skin pathology in a Phase II trial.
March 2026 in “Medeniyet Medical Journal” This study found that hypoxia-conditioned mesenchymal stem cell exosomes increased GM-CSF and decreased IL-1 expression in a dose-dependent manner in a murine model, suggesting potential for treating androgenetic alopecia.